The cofounders of Bind Therapeutics ($BIND), which include MIT professor and entrepreneur Robert Langer, published new data for its targeted nanoparticle platform called Accurins, which are designed to carry drugs to specific parts of the body to treat diseases. The paper, published in the journal Science Translational Medicine, shows the nanoparticles' ability to cross biological barriers including the intestinal epithelial barrier, the pulmonary epithelial barrier, the blood-brain barrier, the fetal-placental barrier and the blood-ocular barrier. "The current findings are expected to significantly broaden the reach of our platform and present opportunities to non-invasively administer Accurins of large molecular weight drugs, such as proteins and RNA, for a myriad of human diseases," said Bind president and CEO Scott Minick in a statement. Release